$IOVA
IOVANCE BIOTHERAPEUTICS, INC.

2021 Q2 Form 10-Q Financial Statement

#000155837021010617 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $19.31M $14.35M $13.86M
YoY Change 34.54% 32.01% 52.64%
% of Gross Profit
Research & Development $62.12M $49.27M $56.95M
YoY Change 26.07% 25.39% 84.28%
% of Gross Profit
Depreciation & Amortization $300.0K $200.0K $252.0K
YoY Change 50.0% -31.03% -7.01%
% of Gross Profit
Operating Expenses $81.43M $63.63M $70.81M
YoY Change 27.97% 26.84% 77.09%
Operating Profit -$81.43M -$63.63M -$70.81M
YoY Change 27.97% 26.84% 77.09%
Interest Expense $75.00K $610.0K $1.220M
YoY Change -87.7% -76.63% -59.87%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$81.35M -$63.02M -$69.60M
YoY Change 29.09% 32.53% 88.36%
Income Tax
% Of Pretax Income
Net Earnings -$81.35M -$63.02M -$69.60M
YoY Change 29.09% 32.53% 88.35%
Net Earnings / Revenue
Basic Earnings Per Share -$0.53 -$0.47
Diluted Earnings Per Share -$0.53 -$0.47 -$549.9K
COMMON SHARES
Basic Shares Outstanding 153.8M 126.9M 126.5M
Diluted Shares Outstanding 153.8M

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $656.4M $771.9M $245.7M
YoY Change -14.97% 90.97% -44.16%
Cash & Equivalents $82.76M $160.6M $52.54M
Short-Term Investments $573.6M $611.3M $193.1M
Other Short-Term Assets $10.27M $10.80M $10.70M
YoY Change -4.89% 58.82% 127.66%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $666.6M $782.7M $256.4M
YoY Change -14.82% 90.46% -42.35%
LONG-TERM ASSETS
Property, Plant & Equipment $80.12M $18.73M $13.61M
YoY Change 327.85% 318.74% 288.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $46.29M
YoY Change
Other Assets $1.150M $3.182M $3.480M
YoY Change -63.86% -4.87% 5.84%
Total Long-Term Assets $186.2M $34.91M $31.92M
YoY Change 433.18% 39.73% 90.56%
TOTAL ASSETS
Total Short-Term Assets $666.6M $782.7M $256.4M
Total Long-Term Assets $186.2M $34.91M $31.92M
Total Assets $852.8M $817.6M $288.3M
YoY Change 4.31% 87.55% -37.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $21.91M $10.24M $10.61M
YoY Change 114.05% -19.9% 39.86%
Accrued Expenses $34.19M $38.79M $22.50M
YoY Change -11.86% 185.88% 165.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $60.53M $54.91M $39.55M
YoY Change 10.25% 62.27% 78.64%
LONG-TERM LIABILITIES
Long-Term Debt $1.000M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $46.84M $2.352M $2.352M
YoY Change 1891.62% 4337.74% 4337.74%
Total Long-Term Liabilities $47.84M $4.353M $5.440M
YoY Change 999.08% -6.71% 22.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $60.53M $54.91M $39.55M
Total Long-Term Liabilities $47.84M $4.353M $5.440M
Total Liabilities $108.4M $59.26M $44.99M
YoY Change 82.89% 53.91% 69.31%
SHAREHOLDERS EQUITY
Retained Earnings -$987.0M -$703.2M -$640.2M
YoY Change 40.35% 53.69% -213502.33%
Common Stock $7.000K $6.000K $5.000K
YoY Change 16.67% 20.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $744.4M $758.3M $243.3M
YoY Change
Total Liabilities & Shareholders Equity $852.8M $817.6M $288.3M
YoY Change 4.31% 87.55% -37.53%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$81.35M -$63.02M -$69.60M
YoY Change 29.09% 32.53% 88.35%
Depreciation, Depletion And Amortization $300.0K $200.0K $252.0K
YoY Change 50.0% -31.03% -7.01%
Cash From Operating Activities -$54.01M -$36.64M -$65.29M
YoY Change 47.4% 8.4% 124.45%
INVESTING ACTIVITIES
Capital Expenditures -$9.611M -$4.970M $637.0K
YoY Change 93.38% 245.14% -22.69%
Acquisitions
YoY Change
Other Investing Activities -$149.6M -$418.8M $100.7M
YoY Change -64.29% -796.69% 5316.13%
Cash From Investing Activities -$159.2M -$423.8M $100.1M
YoY Change -62.44% -822.03% 9590.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $567.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 164.0M 568.5M 3.833M
YoY Change -71.15% 16718.64% -191750.0%
NET CHANGE
Cash From Operating Activities -54.01M -36.64M -65.29M
Cash From Investing Activities -159.2M -423.8M 100.1M
Cash From Financing Activities 164.0M 568.5M 3.833M
Net Change In Cash -49.19M 108.1M 38.65M
YoY Change -145.51% 282.28% -237.73%
FREE CASH FLOW
Cash From Operating Activities -$54.01M -$36.64M -$65.29M
Capital Expenditures -$9.611M -$4.970M $637.0K
Free Cash Flow -$44.40M -$31.67M -$65.93M
YoY Change 40.19% -2.13% 120.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Central Index Key
EntityCentralIndexKey
0001425205
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
146874917
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
154799721
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36860
dei Entity Registrant Name
EntityRegistrantName
IOVANCE BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
75-3254381
dei Entity Address Address Line1
EntityAddressAddressLine1
999 Skyway Road, Suite 150
dei Entity Address City Or Town
EntityAddressCityOrTown
San Carlos
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94070
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
260-7120
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common stock, par value $0.000041666 per value
dei Trading Symbol
TradingSymbol
IOVA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82763000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67329000
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
573605000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
562108000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10272000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6663000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
666640000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
636100000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
80120000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
59159000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
52508000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
54756000
CY2021Q2 us-gaap Long Term Investments
LongTermInvestments
46288000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
6084000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
5525000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1150000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12918000
CY2021Q2 us-gaap Assets
Assets
852790000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
852790000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
768458000
CY2020Q4 us-gaap Assets
Assets
768458000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
21914000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13513000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34192000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
35074000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4428000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6284000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
60534000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
54871000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
46843000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45375000
CY2021Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
1000000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11714000
CY2021Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
47843000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
57089000
CY2021Q2 us-gaap Liabilities
Liabilities
108377000
CY2020Q4 us-gaap Liabilities
Liabilities
111960000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000041666
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000041666
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
154799721
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
146874917
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
33000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
19000
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1731363000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1486662000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-986993000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-830193000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
744413000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
656498000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62119000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49274000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
118068000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
106226000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19307000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14353000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38928000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28211000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
81426000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
63627000
us-gaap Operating Expenses
OperatingExpenses
156996000
us-gaap Operating Expenses
OperatingExpenses
134437000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-81426000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-63627000
us-gaap Operating Income Loss
OperatingIncomeLoss
-156996000
us-gaap Operating Income Loss
OperatingIncomeLoss
-134437000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
75000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
609000
us-gaap Investment Income Interest
InvestmentIncomeInterest
196000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1824000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-81351000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-63018000
us-gaap Net Income Loss
NetIncomeLoss
-156800000
us-gaap Net Income Loss
NetIncomeLoss
-132613000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
153751
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
133162
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
150571
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
129848
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-81351000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-63018000
us-gaap Net Income Loss
NetIncomeLoss
-156800000
us-gaap Net Income Loss
NetIncomeLoss
-132613000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-63000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-595000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
14000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
97000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-81414000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63613000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-156786000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-132516000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
647431000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14414000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
970000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2742000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-63000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
160270000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-81351000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
744413000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
243313000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10537000
CY2020Q2 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
-165000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1237000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-595000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
567000000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-63018000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
758309000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
656498000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31355000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
970000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9221000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
203155000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
14000
us-gaap Net Income Loss
NetIncomeLoss
-156800000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
744413000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
298971000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19949000
us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
-283000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5188000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
97000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
567000000
us-gaap Net Income Loss
NetIncomeLoss
-132613000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
758309000
us-gaap Net Income Loss
NetIncomeLoss
-156800000
us-gaap Net Income Loss
NetIncomeLoss
-132613000
us-gaap Share Based Compensation
ShareBasedCompensation
31355000
us-gaap Share Based Compensation
ShareBasedCompensation
19949000
iova Non Cash Lease Expense
NonCashLeaseExpense
2407000
iova Non Cash Lease Expense
NonCashLeaseExpense
3328000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
3862000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-17000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
738000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
512000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-8159000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1064000
iova Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
159000
iova Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-388000
iova Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3739000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4950000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7096000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-10523000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
18813000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-116399000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-101927000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
320151000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
216678000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
381784000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
534717000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20321000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5612000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-81954000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-323651000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
283000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10191000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5188000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
203155000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
567393000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
214346000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
572298000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
15993000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
146720000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72854000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19419000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88847000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
166139000
iova Unrealized Gain Loss On Short Term Investments
UnrealizedGainLossOnShortTermInvestments
14000
iova Unrealized Gain Loss On Short Term Investments
UnrealizedGainLossOnShortTermInvestments
97000
iova Acquisitions Of Property And Equipment Included In Accounts Payable And Accrued Expense
AcquisitionsOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpense
1378000
iova Acquisitions Of Property And Equipment Included In Accounts Payable And Accrued Expense
AcquisitionsOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpense
5212000
iova Accrued Offering Costs Incurred During Noncash Or Partial Noncash Transaction
AccruedOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction
393000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1000
us-gaap Net Income Loss
NetIncomeLoss
-156800000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-116400000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
203200000
CY2021Q2 iova Ash Cash Equivalents And Short Term Investments And Restricted Cash Total
AshCashEquivalentsAndShortTermInvestmentsAndRestrictedCashTotal
708700000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82800000
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
573600000
CY2021Q2 us-gaap Long Term Investments
LongTermInvestments
46300000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
6100000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
6100000
CY2021Q2 iova Security Deposit For Benefit Of Landlord For Commercial Manufacturing Facility
SecurityDepositForBenefitOfLandlordForCommercialManufacturingFacility
5450000
CY2021Q2 iova Security Deposit For Benefit Of Utilities Service Provider
SecurityDepositForBenefitOfUtilitiesServiceProvider
74685
CY2021Q2 iova Security Deposit For Benefit Of Landlord For New Headquarters Lease
SecurityDepositForBenefitOfLandlordForNewHeadquartersLease
559082
CY2021Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1000000
CY2021Q2 us-gaap Security Deposit
SecurityDeposit
1450000
CY2021Q2 iova Security Deposit For Benefit Of Utilities Service Provider
SecurityDepositForBenefitOfUtilitiesServiceProvider
74685
CY2021Q2 iova Security Deposit For Benefit Of Landlord For New Headquarters Lease
SecurityDepositForBenefitOfLandlordForNewHeadquartersLease
559082
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
6100000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
5500000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82763000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
160614000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
6084000
CY2020Q2 us-gaap Restricted Cash
RestrictedCash
5525000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88847000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
166139000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18769495
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16272855
CY2021Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
682989000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
611828000
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
63096000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
49720000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
573605000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
562108000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
46288000
CY2021Q2 iova Cash Equivalents And Investments
CashEquivalentsAndInvestments
682989000
CY2020Q4 iova Cash Equivalents And Investments
CashEquivalentsAndInvestments
611828000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the assumptions made in valuing stock instruments issued for services and used in measuring operating right-of-use assets and operating lease liabilities, accounting for potential liabilities, capitalization of internal-use software development costs, and the valuation allowance associated with the Company’s deferred tax assets.</span></p>
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
63096000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
49720000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
573605000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
562108000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
46288000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
619893000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
562108000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
619893000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
562108000
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
619860000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
73000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
40000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
619893000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
562089000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
50000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
31000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
562108000
us-gaap Depreciation
Depreciation
700000
us-gaap Depreciation
Depreciation
500000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
573549000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
573605000
CY2021Q2 iova Available For Sale Debt Securities Maturity Rolling After One Through Two Years Amortized Cost
AvailableForSaleDebtSecuritiesMaturityRollingAfterOneThroughTwoYearsAmortizedCost
46311000
CY2021Q2 iova Available For Sale Debt Securities Maturity Rolling After One Through Two Years Fair Value
AvailableForSaleDebtSecuritiesMaturityRollingAfterOneThroughTwoYearsFairValue
46288000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
619860000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
619893000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
86436000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
64737000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6316000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5578000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
80120000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
59159000
CY2021Q2 us-gaap Depreciation
Depreciation
300000
CY2020Q2 us-gaap Depreciation
Depreciation
200000
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
10537000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
31355000
CY2021Q2 iova Clinical Related Expenses Current
ClinicalRelatedExpensesCurrent
13086000
CY2020Q4 iova Clinical Related Expenses Current
ClinicalRelatedExpensesCurrent
15661000
CY2021Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
10210000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
9032000
CY2021Q2 iova Commercial Manufacturing Facility Related Current
CommercialManufacturingFacilityRelatedCurrent
1703000
CY2020Q4 iova Commercial Manufacturing Facility Related Current
CommercialManufacturingFacilityRelatedCurrent
4342000
CY2021Q2 iova Manufacturing Related Expenses Current
ManufacturingRelatedExpensesCurrent
6402000
CY2020Q4 iova Manufacturing Related Expenses Current
ManufacturingRelatedExpensesCurrent
3266000
CY2021Q2 iova Legal And Related Services Current
LegalAndRelatedServicesCurrent
998000
CY2020Q4 iova Legal And Related Services Current
LegalAndRelatedServicesCurrent
1061000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1793000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1712000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34192000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
35074000
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
14414000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
19949000
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
14414000
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
10537000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
31355000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
19949000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
24.38
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.20
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">NOTE 9. LEGAL PROCEEDINGS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Derivative Lawsuit.</span> On December 11, 2020, a purported stockholder derivative complaint was filed by plaintiff Leo Shumacher against the Company, as nominal defendant, and <span style="white-space:pre-wrap;">its current directors, as defendants, in the Court of Chancery in the State of Delaware. The complaint alleges breach of fiduciary duty and a claim for unjust enrichment in connection with alleged excessive compensation of certain non-executive directors of the Company </span>and seeks unspecified damages on behalf of the Company<span style="white-space:pre-wrap;">. The defendants intend to vigorously defend against the foregoing complaints. Based on the early stage of the litigation, it is not possible to estimate the amount or range of possible loss that might result from these matters.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Solomon Capital, LLC.</span> On April 8, 2016, a lawsuit (“the First Solomon Suit”) titled <i style="font-style:italic;">Solomon Capital, LLC, Solomon Capital 401(K) Trust, Solomon Sharbat and Shelhav Raff v. Lion Biotechnologies, Inc.</i> was filed by Solomon Capital, LLC, Solomon Capital 401(k) Trust, Solomon Sharbat and Shelhav Raff (“Solomon Plaintiffs”) against the Company in the Supreme Court of the State of New York, County of New York (index no. 651881/2016). The Solomon Plaintiffs allege that, between June and November 2012, they provided to the Company $0.1 million and that they advanced and paid on behalf of the Company an additional $0.2 million. The complaint further alleges that the Company agreed to (i) provide them with promissory notes totaling $0.2 million, plus interest, (ii) issue a total of 1,110 shares to the Solomon Plaintiffs (after the <span style="-sec-ix-hidden:Hidden_Q30HEw0bPk6cns2m14huPw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">1-for-100</span></span> reverse split of the Company’s common stock effected in March 2013) (the “Equity Claim”), and (iii) allow the Solomon Plaintiffs to convert the foregoing funds into its securities in the next financing of the Company on the same terms offered to other investors, which Solomon Plaintiffs allege, should have given them the right to convert their advances and payments into shares of the Company's common stock in the restructuring that took effect in May 2013. Based on the foregoing, the Solomon Plaintiffs allege causes for breach of contract and unjust enrichment and demand judgment against the Company in an unspecified amount exceeding $1.5 million, plus interest. On June 3, 2016, the Company filed an answer and counterclaims in the lawsuits. The Company has asserted counterclaims for fraudulent inducement, fraudulent misrepresentation, fraudulent concealment, breach of fiduciary duty, and breach of contract, alleging principally that the counterclaim defendants misrepresented their qualifications and failed to disclose that Solomon Sharbat was the subject of an investigation by the Financial Industry Regulatory Authority (“FINRA”) that resulted in the loss of his FINRA license. In its counterclaims, the Company is seeking damages in an amount exceeding $0.5 million and an order rescinding any and all agreements that the plaintiffs contend entitled them to obtain shares of Company stock. On May 12, 2020, the court granted the Company’s motion for summary judgment limiting the Solomon Plaintiffs’ damages for the Equity Claim to $47,420. The Solomon Plaintiffs filed a notice of appeal of this summary judgment on June 9, 2020. On July 2, 2020, the court granted the Company’s motion to dismiss the First Solomon Suit for want of prosecution. On July 31, 2020, the Solomon Plaintiffs, through new counsel, filed a motion for reconsideration of the dismissal of the First Solomon Suit for want of prosecution. On August 11, 2020, the Company filed an opposition brief against the Solomon Plaintiffs’ motion for reconsideration. On August 17, 2020, the Solomon Plaintiffs filed a reply brief in support of their motion for reconsideration. On September 2, 2020, the Solomon Plaintiffs filed a notice of appeal of the dismissal for want of prosecution. On January 4, 2021, the court granted the Solomon Plaintiffs motion for reconsideration, and reinstituted the case. On January 15, 2021, the Company filed a notice of appeal of the court’s grant of the Solomon Plaintiffs motion for reconsideration. On February 10, 2021, the Company filed its opening brief in support of its appeal of the court’s grant of the Solomon Plaintiff’s motion for reconsideration. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On March 24, 2021, the Solomon Plaintiffs filed their brief in opposition to the Company’s appeal of the court’s grant of the Solomon Plaintiff’s motion for reconsideration. On April 2, 2021, the Company filed its reply brief in support of the Company’s appeal of the court’s grant of the Solomon Plaintiffs’ motion for reconsideration. On May 3, 2021, the Solomon Plaintiffs filed their opening brief in support of their appeal of the court’s grant of summary judgment limiting the Solomon Plaintiffs’ damages for the Equity Claim to $47,420. On May 11, 2021, the Appellate Division upheld the court’s grant of the Solomon Plaintiffs’ motion for reconsideration of the dismissal of the First Solomon Suit for want of prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;">On September 27, 2019, the Solomon Plaintiffs filed a new lawsuit (through new legal counsel) (“the Second Solomon Suit”) titled <i style="font-style:italic;">Solomon Capital, LLC, Solomon Capital 401(K) Trust, Solomon Sharbat and Shelhav Raff v. Iovance Biotherapeutics, Inc., f/k/a/ Lion Biotechnologies Inc. f/k/a/ Genesis Biopharma Inc., and Manish Singh</i> in the Supreme Court of the State of New York, County of New York (index no. 655668/2019). In the Second Solomon Suit, the Solomon Plaintiffs allege that they are third party beneficiaries of a “finder’s fee agreement” that prior management entered into with a third party unlicensed entity in 2012 in connection with seeking financing, that an agreement or understanding existed between the Company and the plaintiffs that the plaintiffs would be paid fees and commissions (in cash and stock) if they obtained financing for the Company, and that they directly and indirectly introduced investors to the Company who invested in the Company, or were willing to invest in the Company. Finally, the Solomon Plaintiffs allege that they were promised a license to use the Company’s technology in Israel. The plaintiffs claim that the Company breached the foregoing understandings, promises and agreements and, as a result, they are entitled to certain damages. The Solomon Plaintiffs also allege that Manish Singh, the Company’s former Chief Executive Officer, committed fraud and took shares belonging to them. On February 18, 2020, the Company filed a removal petition and removed the Second Solomon Suit to the U.S. District Court for the Southern District of New York, where the case has been assigned case no. 1:20-cv-1391. On May 22, 2020, the Company moved to dismiss the Second Solomon Suit for lack of personal jurisdiction. On July 17, 2020, the Solomon Plaintiffs filed an opposition brief against the Company’s motion to dismiss for lack of personal jurisdiction. On August 7, 2020, the Company filed a reply brief in support of the Company’s motion to dismiss for lack of personal jurisdiction. On March 26, 2021, the Court denied the Company’s motion to dismiss for lack of personal jurisdiction. The Company filed a response to the complaint in the Second Solomon Suit on April 30, 2021. On May 26, 2021, the Company and Singh filed motions for judgment on the pleadings with respect to the second and third claims asserted against the Company and all claims asserted against Singh, respectively, in the Second Solomon Suit. On June 25, 2021, the Solomon Plaintiffs filed an opposition brief against the motions for judgment on the pleadings. On July 16, 2021, the Company and Singh filed reply briefs in support of the motions for judgement on the pleadings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">The Company intends to vigorously defend these complaints and pursue its counterclaims, as applicable. At the current stage of the litigation, in both the First Solomon Suit and the Second Solomon Suit, it is not possible to estimate the amount or range of possible loss that might result from an adverse judgment or a settlement of these matters. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt;">The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that it believes will result in a probable loss. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company, management does not believe any pending matter will be resolved in a manner that would have a material adverse effect on its financial position, results of operations or cash flows. </p>
CY2021Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
CY2020Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P359M
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
52508000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
54756000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4428000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6284000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
46843000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45375000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
51271000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
51659000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3380000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
2073000
us-gaap Operating Lease Cost
OperatingLeaseCost
6777000
us-gaap Operating Lease Cost
OperatingLeaseCost
3709000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
1578000
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
1260000
us-gaap Variable Lease Cost
VariableLeaseCost
2288000
us-gaap Variable Lease Cost
VariableLeaseCost
2631000
CY2021Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
39000
CY2020Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
14000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
75000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
31000
CY2021Q2 us-gaap Lease Cost
LeaseCost
4997000
CY2020Q2 us-gaap Lease Cost
LeaseCost
3347000
us-gaap Lease Cost
LeaseCost
9140000
us-gaap Lease Cost
LeaseCost
6371000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
2512000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1906000
us-gaap Operating Lease Payments
OperatingLeasePayments
4834000
us-gaap Operating Lease Payments
OperatingLeasePayments
4102000
CY2021Q2 iova Increase Decrease In Right Of Use Assets From Lease Modifications
IncreaseDecreaseInRightOfUseAssetsFromLeaseModifications
-215000
CY2020Q2 iova Increase Decrease In Right Of Use Assets From Lease Modifications
IncreaseDecreaseInRightOfUseAssetsFromLeaseModifications
-151000
iova Increase Decrease In Right Of Use Assets From Lease Modifications
IncreaseDecreaseInRightOfUseAssetsFromLeaseModifications
1943000
iova Increase Decrease In Right Of Use Assets From Lease Modifications
IncreaseDecreaseInRightOfUseAssetsFromLeaseModifications
328000
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P17Y11M19D
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M8D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
5418000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4775000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4423000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4516000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4372000
CY2021Q2 iova Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
74899000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
98403000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
47132000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
51271000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
The granted stock options vest in 12 quarterly installments (with 1/12th of the option shares having vested on the date of grant).
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000

Files In Submission

Name View Source Status
R37.htm Edgar Link pending
0001558370-21-010617-index-headers.html Edgar Link pending
0001558370-21-010617-index.html Edgar Link pending
0001558370-21-010617.txt Edgar Link pending
0001558370-21-010617-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
iova-20210630.xsd Edgar Link pending
iova-20210630x10q.htm Edgar Link pending
iova-20210630x10q001.jpg Edgar Link pending
iova-20210630x10q_htm.xml Edgar Link completed
iova-20210630xex10d1.htm Edgar Link pending
iova-20210630xex10d2.htm Edgar Link pending
iova-20210630xex10d3.htm Edgar Link pending
iova-20210630xex31d1.htm Edgar Link pending
iova-20210630xex31d2.htm Edgar Link pending
iova-20210630xex32d1.htm Edgar Link pending
iova-20210630xex32d2.htm Edgar Link pending
iova-20210630_cal.xml Edgar Link unprocessable
iova-20210630_def.xml Edgar Link unprocessable
iova-20210630_lab.xml Edgar Link unprocessable
iova-20210630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending